Xencor, Inc.
XNCRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Xencor, Inc. (XNCR) is listed under Biotechnology. At a $1.98B market cap, Xencor, Inc. ranks as a small-cap company within healthcare. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Market Cap
$1.98B
Beta
0.88
P/E (TTM)
—
P/E (Fwd)
-7.50
EPS (TTM)
$-2.16
EPS (Fwd)
$-3.55
ROE
-29.1%
ROA
-16.8%
Cash
$456.5M
Total Debt
$170.1M
Free CF
-$94.5M
52W Change
220.2%
Annual Financials
Cash vs Debt
Where XNCR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, XNCR finished 80.17% above its 150-day moving average ($14.93) and 78.98% above its 200-day moving average ($15.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XNCR overbought or oversold?
At the September 3, 2026 close, XNCR's RSI(14) was 63.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $456.5M in cash and $170.1M in debt, XNCR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$94.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -29.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $275.1M to $125.6M.
With cash comfortably exceeding debt, XNCR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Xencor, Inc. and its sector.